Business
Update Regarding Forward Guidance
Renalytix plc clarified its forward revenue guidance, stating that it does not fully incorporate the potential impact of its recent collaboration with Tempus AI, Inc. Due to the early stage of the collaboration, the company is unable to predict the revenue contributions from this relationship. The company intends to provide shareholders with updates on the Tempus collaboration in the future. The kidneyintelX.dkd test has full reimbursement established by Medicare at $950 per reportable result. Disclaimer*
About this update from Renalytix Plc
[{"type":"text","content":"\n\n \nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nUpdate Regarding Forward Guidance\n \nLONDON and NEW YORK, 24 September 2025 - Renalytix plc (LSE: RENX) a precision medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, provides a further comment regarding revenue guidance following the Company's announcement dated 23 September 2025.\n \nThe Company would like to clarify that the forward revenue guidance provided does not include full consideration of the implications of its recently announced collaboration with Tempus AI, Inc. (\"Tempus\"). As it is too early to predict revenue contributions from this new relationship with Tempus, the Company expects to provide shareholders with updates in due course.\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix Plc\nJames McCullough, CEO\n \n\n\nwww.renalytix.com\nVia Walbrook PR\n\n\n\n\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\nJeff Keating / David Hignell (Corporate Finance)\nVadim Alexandre (Corporate Broking)\n \n\n\nTel: 0203 470 0470\n \n\n\n\n\nOberon Capital (Sole Bookrunner and Joint Broker)\nMike Seabrook / Nick Lovering / Aimee McCusker\n \n\n\nTel: 020 3179 5300\n \n\n\n\n\nWalbrook PR Limited\nPaul McManus / Alice Woodings\n\n\nTel: 020 7933 8780 or [email protected]\nMob: 07980 541 893 / 07407 804 654\n \n\n\n\n\n\n\n\n\n\n \nThe person responsible for making this Announcement on behalf of the Company is\nJames McCullogh, Chief Executive Officer.\n \n \nAbout Renalytix (www.renalytix.com)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.\n \nUnrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of developmen...